Trial Profile
A Study to Evaluate the Role of E-Cadherin and Vimentin as Biomarkers of Clinical Outcomes in Lung Adenocarcinoma Patients Treated with Erlotinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms CLICaP
- 15 Dec 2015 New trial record